A

Axis Heilsa S. de R.L. de C.V. | Althian Clinical Research

Research site

(Unclaimed)

Location

Capitán Lorenzo Aguilar Sur 669., Monterrey, Nuevo Leon, Mexico

Site insights

Top conditions

Top treatments

Pembrolizumab

Anastrozole

Imlunestrant

Sacituzumab

Enzalutamide

Exemestane

Talazoparib

Tamoxifen

Sunitinib

Letrozole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 7 total trials

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Placebo

Drug: Pemetrexed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Active, not recruiting

Breast Neoplasms

Drug: Anastrozole

Drug: Tamoxifen

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (TroFuse-007)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall s...

Enrolling

Non-small Cell Lung Cancer (NSCLC)

Biological: Pembrolizumab

Biological: Sacituzumab tirumotecan

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting

Prostate Cancer

Drug: Placebo plus enzalutamide

Drug: talazoparib plus enzalutamide